long intergenic non-protein coding RNA 1551Genealiases: C14orf23 · c14_5148
Q-omics provides the consensus-scored LINC01551 profile across patient tissues and cancer cell-line models. LINC01551 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01551 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, LINC01551 RNA expression shows 6,975 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, COAD, and STAD as cancer lineages where LINC01551 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01551 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01551 survival associations across molecular data types. LINC01551 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01551 RNA expression–survival associations across cancer types. High LINC01551 expression shows unfavorable associations in KIRC, UVM, ACC, BRCA, KICH and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01551 RNA expression.
This table summarizes LINC01551 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01551. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01551 shows lower tumor expression in THCA, HNSC and KICH and higher tumor expression in COAD and LUSC. The COAD box plot shows higher LINC01551 RNA expression in tumor versus normal tissue (log2 FC = +0.064, t-test p = .029).
This table shows molecular features associated with LINC01551 in patient tissues and cancer cell lines. In patient samples, LINC01551 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC01551 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
